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Beta-Adrenergic Blocking Agents in Congestive Heart Failure
Sidney Goldstein, MD'

Although recent physiologic studies suggest that increased catecholamine release in humans may in
the long run represent an adverse homeostatic mechanism, this catecholamine release is acutely
important in permitting human response to stress. Clinical interventions with beta-adrenergic
blocking agents have showed a salutary effect on cardiacfunction in patients with severe heart failure:
in patients with heart failure associated with myocardial infarction, these agents may help improve
mortality rates. These studies indicate that the drugs are well tolerated when used carefully in these
high-risk patients. (Henry Ford Hosp Med J 1986:34:184-7)

R

ecent clinical investigations suggest that beta-adrenergic
blocking agents may have a beneficial role in the treatment
of patients with heart failure. This appears paradoxical, since
this class of drugs has long been known to have a negative
inotropic effect. Nevertheless, a series of clinical studies suggests that these agents may be effective in certain patients with
heart failure. Investigations have been canied out in two groups
of patients: those with heart failure due to primary cardiomyopathy (1-5), and those who experience heart failure in association
with a recent acute myocardial infarction (6-8). The investigations of beta-adrenergic blocking agents in primary cardiomyopathy have examined patients' physiologic responses to
these drugs. Since the number of patients available for such
studies is limited, information is not yet available regarding the
long-term effect of beta-blocking agents on mortality. Clinical
trials, however, are planned to explore this issue. Conversely,
patients with recent myocardial infarction associated with heart
failure were studied not only to examine the effects of these
dmgs on morbidity and mortality but also to determine whether
adverse dmg reactions occuned.

Norepinephrine in Heart Failure
These clinical studies, coupled with the observation that the
mortality rate of heart failure appears to be directly related to
norepinephrine concentration (9), have not only encouraged investigation of the neurohumoral response to heart failure but
also increa.sed our understanding of norepinephrine and its role
in heart failure. Although it was recendy observed that plasma
norepinephrine concentration is increased in patients with heart
failure, we have known for some time that the concentration of
catecholamine in the myocardium is decreased (10-12).
These observations suggest that myocardial norepinephrine
uptake is decreased or that the rate of norepinephrine turnover
or clearance in the failing myocardial tissue is accelerated. The
reflex-neurohumoral response to heart failure is usually accompanied by norepinephrine release. In the setting of a falling cardiac output, norepinephrine maintains systemic blood pressure
by vasoconstriction. The decreased myocardial catecholamine
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concentration is thought to be caused by chronic increased sympathetic discharge which is required for the maintenance of
blood pressure. The decreased myocardial norepinephrine concentration resuldng from the chronic neurosympathetic activity
may explain the myocardial beta-adrenergic receptor downregulation (13). This down-regulation of beta-receptors partly
explains the failure of the myocardium to respond to increased
norepinephrine concentration in the blood. Studies of norepinephrine clearance in patients with heart failure indicate that
the increased semm norepinephrine content is a function of both
increased norepinephrine release and a decrease in regional norepinephrine clearance in the specific coronary vascular bed (14).
This combination of increa.sed norepinephrine secretion and decreased clearance is observed in cardiac and renal beds but not in
the pulmonary bed. Although increased norepinephrine is critical to the eariy adaptation to a fall in cardiac output, in the long
mn beta-receptor down-regulation and decreased clearance of
norepinephrine render adrenergic stimulation less important for
the maintenance of cardiac homeostasis. In fact, increased
semm norepinephrine concentration may be detrimental to cardiac function, leading to increased work load of the heart resulting from alpha-receptor stimulation and increased systemic
vascular resistance. Continued myocardial stimulation may also
lead to acceleradon of myocardial degeneration (15), promoting
cardiac anhythmias and sudden death (16).
The relationships between circulatory and myocardial norepinephrine, beta-receptor regulation, and cardiac function at
rest and during stress are shown in Figs 1 and 2. In the setting of
heart failure, an increase occurs in circulating norepinephrine
stores. This increase in circulatory norepinephrine results in an
increased peripheral resistance in the setting of decreased left
ventricular function (Fig I). With stress in the failing heart, a
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Fig I—The relationship between circulatory norepinephrine (NE), beta-receptor regulation, peripheral resistance, and left ventricular function (LV Ex) in the normal individual
and the individual with heart failure.
slight increase in left ventricular function occurs as a result of a
marked increase in circulating norepinephrine, but is associated
with a further exaggeration of systemic resistance (Fig 2).

Beta Blockers in Cardiomyopathy
The seminal clinical studies by Waagstein et al (I), in which
metoprolol was administered to patients having heart failure
predominantly due to primary cardiomyopathy, first explored

the potential of this therapy. Most recently, Engelmeier and colleagues (4) examined the effect of graded doses of metoprolol on
cardiac function in patients with primary cardiomyopathy. Incremental doses of metoprolol were carefully administered to
patients up to when either the daily dose of 100 mg was reached
or a systolic pressure of 90 mm Hg or a pulse rate of 60 was
achieved. The endpoints of therapy were attained in 20 of 21
patients.
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Fig 2—Similar relationship of normal individual and heartfailure individual during stress.
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Table
Efficacy of Beta-Blocking Agents in Heart Failure
No. of
Tolal Death
Sudden Death
Study
Drug
Patients Placebo Control Placebo Control
Hansteen et al (6) Propranolol
560
13.1% 9.0%
8.2% 4,0%
Australian/
Swedish
study(7)
Pindolol
529
17.7% 17.1% 11.7% 10.6%
Beta Blocker
Heart Attack
Trial subgroup
analysis(l)
Propranolol
710
18.4% 13.3% 10.4% 55.5%

Once metoprolol dosage was established, 14 of the 20 patients
experienced improved exercise tolerance, and seven of 20
achieved an improvement in ejection fraction and fall of the left
ventricular end-diastolic pressure to almost normal levels. The
changes took place over a three-month period. Only rare, adverse effects that could not be dealt with by prolongation of dosage interval were observed. The effect of the drug appeared to be
closely related to its bradycardic effect. Similar results were reported by Svedberg et al (2). Other studies of mixed patient populations with heart failure due to diverse causes failed to show a
beneficial effect of metoprolol when changes were measured
within one month (3,5). Engelmeier et al (4) suggest that the effect of metoprolol requires treatment for a longer duration.
These studies suggest that beta-adrenergic blocking agents
may produce a beneficial effect in heart failure patients. Patient
candidates include those with tachycardia and perhaps hypertension. The only drug used in these treatment programs was
metoprolol, a cardioselective drug. A case can be made that
these should be the most appropriate beta blockers to use, since
the increased vasoconstriction occasionally observed with nonselective dmgs could modify the effects of these drugs. The effects of these dmgs which also result in alpha-blockade may also
be modified by decreasing peripheral resistance.

Beta-Blocking Agents in Congestive Heart Failure
Associated with Coronary Heart Disease
The results of beta blocker studies in postinfarction patients
with heart failure are listed in the Table, The two prospective
studies were not specifically designed to study the effect of these
agents in postinfarction patients with heart failure alone, A Norwegian study (6) and a combined Australian/Swedish study (7)
examined high-risk postmyocardial infarction individuals in
whom heart failure was one of the major characteristics. Also
included in these study populations, however, were patients with
ventricular ectopy and serious cardiac rhythm disturbances. The
Norwegian study of high-risk postmyocardial infarction patients
observed that total and sudden death mortality decreased to 32%
(p value not significant) and 50% (p < 0,05) when patients were
treated with propranolol. In the combined Australian/Swedish
multicenter study with pindolol, no significant beneficial effect
was observed in patients treated with that beta blocker This lack
of effect may be attributed to the intrinsic sympathomimetic-
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stimulating activity characteristics of pindolol. The incidence of
heart failure in the active treatment program in both studies was
slightly higher than in the placebo group. In the Norwegian propranolol study, the occunence of heart failure in the first two
weeks of therapy was 6.5% in the propranolol group and 1.8% in
the placebo group. After two weeks this adverse effect related to
propranolol disappeared and was 1.4% in the propranolol group
and 3.9% in the placebo group.
A retrospective subgroup analysis was conducted in the Beta
Blocker Heart Attack Trial (8), examining patients who had experienced congestive heart failure priorto randomization. In
this ix)stmyocardial infarction study, the total mortality over the
25-month average follow-up in the patients with heart failure
treated with propranolol was 13.3% compared to 18.4% in the
placebo group; in those without heart failure, the mortality was
5.9% and 7.8%. The decrease in total mortality, 27% and 25%,
respectively, was similar regardless of the history of heart
failure. Patients with heart failure, however, did experience a
greater absolute benefit with beta blockers because of the increase in mortality rate in general. An impressive 47% decrease
in the rate of sudden death was observed in the propranololtreated patients with a history of heart failure, compared to a
13% decrease in those without heart failure. However, a slight
increase of heart failure did occur during the first 30 days of propranolol administration in patients having a history of heart
failure. The overall incidence of heart failure during follow-up
was similar in the placebo-treated and propranolol-treated patients regardless of whether they had previous heart failure.
The mechanism by which beta blockers modify mortality in
coronary heart disease patients is not entirely clear Patients with
heart failure are known to have increased ventricular ectopy.
In the Beta Blocker Heart Attack Trial (8), 19.6% of the patients with a history of heart failure had > 10 ventricular premature beats/hr compared to 11,8% of those without a history of
heart failure, A similar increased frequency of ventricular complex ectopy was observed in padents with heart failure (50,2%)
compared to those without a history of heart failure (38,6%)
(p < 0,05). Beta blockers have been shown to decrease ventricular ectopy in patients with coronary heart disease. This
particular effect may explain the observed decrease in total
mortality, particularly in view of the decreased rate of sudden
death in propranolol-treated patients. However, whether this decreased frequency of ventricular ectopy is an antiarrhythmic
effect or is due to the ability of beta blockers to modulate myocardial ischemia is unclear. Antiarrhythmic effects of beta
blockers have been demonstrated in patients without ischemic
heart disease (17). In animal models, beta blockers have been
shown to decrease ventricular fibrillation threshold in both ischemic and nonischemic animals (18).
Engelmeier et al (4) suggest a number of other possible mechanisms by which beta-adrenergic blocking dmgs can exert their
action. They suggest that these dmgs may block the cardiotoxic
effects of catecholamines, restore the down-regulation of betaadrenergic receptors, or modulate inappropriate tachyarrhythmias. The restoration of normal receptor regulation occurs
as a result of chronic beta-receptor blockade, rendering these
receptors more sensitive to beta stimulation. Regardless of
the proposed mechanism, the demonstration of their clinical
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efficacy has stimulated considerable research on how these
dmgs can modify both symptomatology and mortality.
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